Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
Open Access
- 13 March 2015
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (8) , 1179-1188
Abstract
Purpose Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL. Methods We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients’ baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage. Results A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6 % women; 80.7 % papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9 % women; 76.3 % papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample. Conclusion Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients’ wellbeing, support needs, and disease experience.Keywords
This publication has 38 references indexed in Scilit:
- Normative Data of the EORTC QLQ-C30 For the German Population: A Population-Based SurveyPLOS ONE, 2013
- The Computer-based Health Evaluation Software (CHES): a software for electronic patient-reported outcome monitoringBMC Medical Informatics and Decision Making, 2012
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerNew England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- Health‐related quality of life among thyroid cancer survivors: a systematic reviewClinical Endocrinology, 2011
- Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in KoreaHealth and Quality of Life Outcomes, 2010
- Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled studyClinical Endocrinology, 2009
- The Impact of Thyroid Cancer and Post-Surgical Radioactive Iodine Treatment on the Lives of Thyroid Cancer Survivors: A Qualitative StudyPLOS ONE, 2009
- Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapySupportive Care in Cancer, 2003
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993